Funding for this research was provided by:
Taiho Pharmaceutical Co., Ltd.
Article History
Received: 22 October 2021
Accepted: 1 March 2022
First Online: 4 April 2022
Change Date: 8 May 2022
Change Type: Update
Change Details: Corrections have been made in Table 3 and Figure 4 caption
Declarations
:
: YN has received grant support from Taiho Pharmaceutical Co., Ltd to their institution for manuscript preparation, has received grants from Taiho Pharmaceutical Co., Ono Pharmaceutical, Taiho Pharmaceutical Co., Eisai, Daiichi Sankyo, Stella-Pharma, Ohara, Denba and AbbVie to their institution in the past 3 years, has received consulting fees from AbbVie in the past 3 years and has received payments or honoraria from Chugai, Ono Pharmaceutical, Daiichi Sankyo, Eisai and Novocure in the past 3 years. YO has no conflicts of interest to disclose. YA has received grant support from Taiho Pharmaceutical Co., Ltd to their institution for manuscript preparation, has received grants from Siemens, Philips, Sanofi, Ono Pharmaceutical, Sanofi, Nihon Medi Physics, Brainlab, Carl Zeiss, Tanabe Mitsubishi, Chugai, Eisai, Merck, Meiji Seika, Daiichi Sankyo, CSL Behring, Takeda, Pfizer, Stryker and Astellas Pharma to their institution in the past 3 years and has received payments or honoraria from Nippon Kayaku, Novocure, UCB Japan, Ono Pharmaceutical, Brainlab, Chugai, Merck, Eisai, Meiji Seika, Daiichi Sankyo, CSL Behring, Integra Japan, Carl Zeiss, Otsuka and AbbVie in the past 3 years.
: All patients provided written informed consent to participate in the study.
: The clinical study protocol, investigator’s brochure, a sample informed consent form and other study-related documents were reviewed and approved by the local of all study sites. Each investigator conducted the study according to applicable local or regional regulatory requirements and in accordance with the ethical principles of the Declaration of Helsinki, the International Council for Harmonisation Harmonised Tripartite Guideline for Good Clinical Practice and Institutional Review Board regulations.